- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Emerging agents and regimens for AML ; volume:14 ; number:1 ; day:23 ; month:3 ; year:2021 ; pages:1-20 ; date:12.2021
Journal of hematology & oncology ; 14, Heft 1 (23.3.2021), 1-20, 12.2021
- Urheber
-
Liu, Hongtao
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-021-01062-w
- URN
-
urn:nbn:de:101:1-2021050807302756729820
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Liu, Hongtao
- SpringerLink (Online service)
Ähnliche Objekte (12)
Emerging agents and regimens for multiple myeloma
Emerging agents and regimens for polycythemia vera and essential thrombocythemia
New agents and regimens for diffuse large B cell lymphoma
Clinical results of hypomethylating agents in AML treatment
Emerging therapeutic agents for lung cancer
Emerging therapeutic agents for genitourinary cancers
Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
AML
AML
AML
Emerging agents and regimens for multiple myeloma
Emerging agents and regimens for polycythemia vera and essential thrombocythemia
New agents and regimens for diffuse large B cell lymphoma
Clinical results of hypomethylating agents in AML treatment
Emerging therapeutic agents for lung cancer
Emerging therapeutic agents for genitourinary cancers
Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
AML
AML
AML
Emerging agents and regimens for multiple myeloma
Emerging agents and regimens for polycythemia vera and essential thrombocythemia
New agents and regimens for diffuse large B cell lymphoma
Clinical results of hypomethylating agents in AML treatment
Emerging therapeutic agents for lung cancer
Emerging therapeutic agents for genitourinary cancers
Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
AML
AML